Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 12, 2015, Pages 2154-2159

  Burke, Michael J ^a   Verneris, Michael R ^b   Le Rademacher, Jennifer ^c   He, Wensheng ^c   Abdel Azim, Hisham ^d   Abraham, Allistair A ^e   Auletta, Jeffery J ^f   Ayas, Mouhab ^g   Brown, Valerie I ^h   Cairo, Mitchell S ⁱ   Chan, Ka Wah ^j   Diaz Perez, Miguel A ^k   Dvorak, Christopher C ^l   Egeler, R Maarten ^m   Eldjerou, Lamis ⁿ   Frangoul, Haydar ^o   Guilcher, Gregory M T ^p   Hayashi, Robert J ^q   Ibrahim, Ahmed ^r   Kasow, Kimberly A ^s   Leung, Wing H ^t   Olsson, Richard F ^u,v   Pulsipher, Michael A ^d   Shah, Niketa ^w   Shah, Nirali N ^x   Thiel, Elizabeth ^c   Talano, Julie An ^a   Kitko, Carrie L ^y   more..

^a Children's Hospital of Wisconsin   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f NATIONWIDE CHILDREN S HOSPITAL   (United States)

^g KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^h PENN STATE COLLEGE OF MEDICINE   (United States)

ⁱ NEW YORK MEDICAL COLLEGE   (United States)

^j TEXAS TRANSPLANT INSTITUTE   (United States)

^k HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m HOSPITAL FOR SICK CHILDREN   (Canada)

ⁿ UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^o VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p ALBERTA CHILDREN'S HOSPITAL   (Canada)

^q WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r MAKASSED GENERAL HOSPITAL   (Lebanon)

^s UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^t ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^u KAROLINSKA INSTITUTE   (Sweden)

^v UPPSALA UNIVERSITY   (Sweden)

^w PHOENIX CHILDREN'S HOSPITAL   (United States)

^x NATIONAL CANCER INSTITUTE   (United States)

^y VANDERBILT UNIVERSITY   (United States)

more..

Author keywords

Acute lymphoblastic leukemia; Pediatric; Relapse; T cell ALL; Transplantation

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PNEUMONIA; RELAPSE; REMISSION; SCHOOL CHILD; SIBLING; SYNDROME; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; T LYMPHOCYTE; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; ACUTE DISEASE; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CLINICAL TRIAL; GRAFT VS HOST DISEASE; IMMUNOLOGY; INTERNATIONAL COOPERATION; MULTICENTER STUDY; PATHOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROCEDURES; PROSPECTIVE STUDY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ACUTE DISEASE; ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONAL COOPERATION; MALE; MYELOABLATIVE AGONISTS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84947443750     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.08.023     Document Type: Article

References (30)

1. Gurney J.G., Severson R.K., Davis S., Robison L.L. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995, 75:2186-2195.
2. Crist W., Boyett J., Pullen J., et al. Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. Med Pediatr Oncol 1986, 14:135-139.
3. Pullen J., Shuster J.J., Link M., et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 1999, 13:1696-1707.
4. Ludwig W.D., Teichmann J.V., Sperling C., et al. [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies]. Klin Padiatr 1990, 202:243-252.
5. Uckun F.M., Sensel M.G., Sun L., et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998, 91:735-746.
6. Hunger S.P., Lu X., Devidas M., et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012, 30:1663-1669.
7. Pui C.H., Sallan S., Relling M.V., et al. International childhood acute lymphoblastic leukemia workshop: Sausalito, CA, 30 November-1 December 2000. Leukemia 2001, 15:707-715.
8. Asselin B.L., Devidas M., Wang C., et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 2011, 118:874-883.
9. Rives S., Estella J., Camos M., et al. [T-cell pediatric acute lymphoblastic leukemia: analysis of survival and prognostic factors in 4 consecutive protocols of the Spanish cooperative study group SHOP]. Med Clin (Barc) 2012, 139:141-149.
10. Reiter A., Schrappe M., Ludwig W.D., et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994, 84:3122-3133.
11. Lauten M., Moricke A., Beier R., et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica 2012, 97:1048-1056.
12. Schrappe M., Valsecchi M.G., Bartram C.R., et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011, 118:2077-2084.
13. Nguyen K., Devidas M., Cheng S.C., et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008, 22:2142-2150.
14. Reismuller B., Peters C., Dworzak M.N., et al. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group. J Pediatr Hematol Oncol 2013, 35:200-204.
15. Einsiedel H.G., von Stackelberg A., Hartmann R., et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005, 23:7942-7950.
16. Bakr M., Rasheed W., Mohamed S.Y., et al. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012, 18:1897-1904.
17. Harvey J., Green A., Cornish J., et al. Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of high-resolution matching at HLA class I and II. Bone Marrow Transplant 2012, 47:1294-1300.
18. Mateos M.K., O'Brien T.A., Oswald C., et al. Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review. Pediatr Blood Cancer 2013, 60:1520-1527.
19. Flowers M.E., Kansu E., Sullivan K.M. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999, 13:1091-1112. viii-ix.
20. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
21. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
22. Klein J. Survival analysis: techniques of censored and truncated data 2003, Springer Verlag, New York, NY. 2nd ed.
23. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
24. Kaplan E.L. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
25. Henze G., Fengler R., Hartmann R., et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991, 78:1166-1172.
26. Tallen G., Ratei R., Mann G., et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010, 28:2339-2347.
27. Ko R.H., Ji L., Barnette P., et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 2010, 28:648-654.
28. Oliansky D.M., Camitta B., Gaynon P., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biol Blood Marrow Transplant 2012, 18:979-981.
29. Pulsipher M.A., Langholz B., Wall D.A., et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood 2014, 123:2017-2025.
30. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.